Orthofix Medical Inc. maintains its primary corporate headquarters and executive administrative offices in Lewisville, Texas, United States. As a global medical technology enterprise specializing in spine and orthopedic solutions, the company also operates key research, manufacturing, and surgeon education hubs in Carlsbad, California, alongside international facilities located in Verona, Italy, and various other global offices.
Clinical and scientific evidence demonstrates that Orthofix's medical devices and orthopedic systems achieve high rates of clinical efficacy when utilized according to strict manufacturer guidelines and physician instructions.
Wall Street equity research analysts covering Orthofix Medical Inc. (NASDAQ: OFIX) maintain a general consensus rating leaning toward a Buy.
When discussing medical devices or orthopedic care frameworks, "Safix" (or similar variant terminology associated with casting, bandaging, or stabilization products) typically presents minimal localized risks.
Clinical studies evaluating non-invasive bone growth stimulators (which utilize pulsed electromagnetic field or low-intensity ultrasound technology to promote healing in non-union fractures or spinal fusions) generally report high clinical success ra...
The out-of-pocket rental cost for a prescription bone growth stimulator varies significantly depending on health insurance coverage, Medicare provider fee schedules, and specific device models.
Orthofix Medical Inc.
Orthofix Medical Inc.
The President and Chief Executive Officer of Orthofix Medical Inc. is Massimo Calafiore, who also serves as a member of the company's Board of Directors.
The prescribed duration for wearing a non-invasive bone growth stimulator varies significantly based on the specific anatomical location of the fracture, the severity of the non-union or spinal fusion, and the attending physician's clinical instructi...
Orthofix Inc. previously faced high-profile federal scrutiny and a major whistleblower False Claims Act lawsuit that resulted in a $42 million global criminal and civil resolution with the U.S. Department of Justice.
When referring to pharmaceutical products like the OFIX tablet (which contains the fluoroquinolone antibiotic ofloxacin), potential side effects can include gastrointestinal discomfort such as nausea, mild diarrhea, abdominal cramps, headaches, dizzi...
Bone growth stimulators are generally considered exceptionally safe medical devices with minimal adverse side effects.
The corporate net worth or market capitalization of Orthofix Medical Inc. (NASDAQ: OFIX) fluctuates dynamically during active trading hours on the Nasdaq exchange based on share price changes and total outstanding common stock.
Prescription bone growth stimulators are high-end medical devices, with retail purchase costs or monthly commercial rental fees ranging broadly from $2,000 to over $4,000 per month depending on the specific model and treatment duration required.
No, Orthofix Medical Inc. is not a private company. It is a publicly traded global medical technology enterprise listed on the Nasdaq Global Select Market under the ticker symbol OFIX.
The cost of an Orthofix bone growth stimulator (such as their proprietary spine or extremity therapy units) varies depending on insurance contractual agreements, Medicare fee schedules, and whether the device is rented or purchased.
Yes, Orthofix's core medical devices and bone growth therapy systems are FDA approved or cleared for commercial distribution and clinical use in the United States.
Depending on the context of your inquiry, OFIX can refer to multiple distinct entities. In financial markets, OFIX is the ticker symbol for Orthofix Medical Inc.
Yes, Medicare generally covers bone growth stimulators, but coverage is strictly regulated and contingent upon meeting precise medical necessity criteria.
Orthofix Medical Inc. is recognized as an established global medical technology enterprise dedicated to advancing spine and orthopedic care solutions.
Orthofix Medical Inc. maintains a dedicated global workforce comprising approximately 1,300 to 1,600 employees worldwide.
The Ofix 200 Tablet is a prescription fluoroquinolone antibiotic containing 200mg of ofloxacin as its active pharmaceutical ingredient.
Supporting bone fracture healing and overall skeletal health through nutrition requires adequate intake of calcium, protein, and essential micronutrients.
The financial cost of an Orthofix bone growth stimulator varies substantially depending on whether the device is rented or purchased, insurance contract terms, and specific Medicare fee schedules.
Revo Health operates as a prominent management services organization partnering with specialized healthcare practices like Twin Cities Orthopedics.